Cost-effectiveness of HIV screening of blood donations in Accra (Ghana)

Value in Health

Volumn 11, Issue 5, 2008, Pages 809-819

  Van Hulst, Marinus ^a,b   Sagoe, Kwamena W C ^c   Vermande, Jacobien E ^a   Van Der Schaaf, Ido P ^a,d   Van Der Tuuk Adriani, Willem P A ^e   Torpey, Kwasi ^f   Ansah, Justina ^g   Mingle, Julius A A ^c   Sibinga, Cees Th Smit ^e   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b MARTINI HOSPITAL   (Netherlands)

^c UNIVERSITY OF GHANA   (Ghana)

^d ATHENA INSTITUTE   (Netherlands)

^e Sanquin Consulting Services   (Netherlands)

^f FAMILY HEALTH INTERNATIONAL   (United States)

^g National Blood Transfusion Service   (Ghana)

Author keywords

Blood transfusion; Cost effectiveness; Developing countries; NAT; Screening

Indexed keywords

ANTIGEN P24;

ADOLESCENT; ADULT; ANTIBODY SCREENING; ARTICLE; BLOOD BANK; BLOOD DONOR; BLOOD TRANSFUSION; CHILD; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION TREE; FEMALE; GHANA; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID AMPLIFICATION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT; TEACHING HOSPITAL; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

EID: 52649126283     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00337.x     Document Type: Article

References (39)

1. Ministry of Health/Ghana Health Service. 2004 HIV Sentinel Survey Report. Accra : Ministry of Health/Ghana Health Service, 2005.
2. Ministry of Health/Ghana Health Service. HIV/AIDS in Ghana. Accra : National AIDS/STI Control Programme/Ghana Health Service, 2005.
3. Candotti D, Sarkodie F, Allain JP. Residual risk of transfusion in Ghana. Br J Haematol 2001 113 : 37 9.
4. Marshall DA, Kleinman SH, Wong JB, et al. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang 2004 86 : 28 40.
5. Jackson BR, Busch MP, Stramer SL, Aubuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003 43 : 721 9.
6. Sarkodie F, Adarkwa M, du-Sarkodie Y, et al. Screening for viral markers in volunteer and replacement blood donors in West Africa. Vox Sang 2001 80 : 142 7.
7. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996 334 : 1685 90.
8. Baltussen R, Stolk E, Chisholm D, Aikins M. Towards a multi-criteria approach for priority setting: an application to Ghana. Health Econ 2006 15 : 689 96.
9. World Bank. World Development Report 1993. New York : Oxford University Press, 1993.
10. World Health Organization. Investing in Health Research and Development: Report of the Ad Hoc Committee on Health Research Relating to Future Intervention Options. Geneva : WHO, 1996.
11. Creese A, Floyd K, Alban A, Guinness L. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet 2002 359 : 1635 43.
12. Hogan DR, Baltussen R, Hayashi C, et al. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ 2005 331 : 1431 7.
13. Murray CJL, Lopez AD. The Global Burden of Disease. A Comprehensive Assessment of Mortality and Disability for Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Cambridge, MA : Harvard University Press, 1996.
14. World Bank. GNI per capita in 2004, Atlas method and PPP. Available from: http://www.worldbank.org/data/databytopic/GNIPC.pdf [Accessed August 1, 2005].
15. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998 18 (2 Suppl. S68 80.
16. Briggs AH, O'Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 2002 23 : 377 401.
17. Kleinman S, Busch MP, Korelitz JJ, Schreiber GB. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev 1997 11 : 155 72.
18. Torpey EK. Estimating the Cost of HIV Related Clinical Care Services. Accra : Family Health International, 2003.
19. Anonymous. Improved methods and assumptions for estimation of the HIV/AIDS epidemic and its impact: recommendations of the UNAIDS Reference Group on Estimates, Modelling and Projections. AIDS 2002 16 : W1 14.
20. Deuchert E, Brody S. Plausible and implausible parameters for mathematical modeling of nominal heterosexual HIV transmission. Ann Epidemiol 2007 17 : 237 44.
21. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai. Uganda Lancet 2001 357 : 1149 53.
22. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005 191 : 1403 9.
23. Schmid GP, Buve A, Mugyenyi P, et al. Transmission of HIV-1 infection in sub-Saharan Africa and effect of elimination of unsafe injections. Lancet 2004 363 : 482 8.
24. World Health Organization. Life Tables for 191 Countries, Ghana 2001. Available from: http://www3.who.int/whosis/life/life_tables/life_tables_process. cfm?country=gha&year=2001 [Accessed January 21, 2004].
25. Vamvakas EC, Taswell HF. Epidemiology of blood transfusion. Transfusion 1994 34 : 464 70.
26. Tynell E, Norda R, Shanwell A, Bjorkman A. Long-term survival in transfusion recipients in Sweden, 1993. Transfusion 2001 41 : 251 5.
27. Anonymous. Predicting the failure of 3 by 5. Lancet 2005 365 : 1597.
28. Felling B, Amenyah J, Sam-Abbenyi A, et al. Ghana: Preparing for the Management of Antiretroviral Drugs - Findings and Recommendations of the ARV Assessment Team. Arlington, VA : John Snow Inc./DELIVER/U.S. Agency for International Development, 2003.
29. Sterne JA, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005 366 : 378 84.
30. Beck EJ, Mandalia S, Gaudreault M, et al. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. AIDS 2004 18 : 2411 18.
31. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006 20 : 1181 9.
32. Ekwueme DU, Weniger BG, Chen RT. Model-based estimates of risks of disease transmission and economic costs of seven injection devices in sub-Saharan Africa. Bull World Health Organ 2002 80 : 859 70.
33. Goodman CA, Coleman PG, Mills AJ. Cost-effectiveness of malaria control in sub-Saharan Africa. Lancet 1999 354 : 378 85.
34. Wang B, Schreiber GB, Glynn SA, et al. Does prevalence of transfusion-transmissible viral infection reflect corresponding incidence in United States blood donors? Transfusion 2005 45 : 1089 96.
35. Moore A, Herrera G, Nyamongo J, et al. Estimated risk of HIV transmission by blood transfusion in Kenya. Lancet 2001 358 : 657 60.
36. Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings - the case of Cote d'Ivoire. N Engl J Med 2006 355 : 1141 53.
37. Owusu-Ofori S, Temple J, Sarkodie F, et al. Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings. Transfusion 2005 45 : 133 40.
38. Heyns Ad, Benjamin RJ, Swanevelder JPR, et al. Prevalence of HIV-1 in blood donations following implementation of a structured blood safety policy in South Africa. JAMA 2006 295 : 519 26.
39. African Development Bank and Organisation for Economic Co-operation and Development, Ghana, eds. African Economic Outlook (2004/2005 edn). Paris : OECD Publishing, 2005.